Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01471522 · ClinicalTrials.gov registry record · NA

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

A NA study of Cardiovascular Diseases and Coronary Artery Disease, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
5,179
Enrollment target
20
Study locations

NCT01471522 is a NA study of Cardiovascular Diseases and Coronary Artery Disease that has completed, run by NYU Langone Health. The registered enrollment target is 5,179 participants, below the 26,957-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01471522, a NA study of Cardiovascular Diseases and Coronary Artery Disease, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
5,179 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the ISCHEMIA trial is to determine the best management strategy for higher-risk patients with stable ischemic heart disease (SIHD). This is a multicenter randomized controlled trial with 5179 randomized participants with moderate or severe ischemia on stress testing. A blinded coronary computed tomography angiogram (CCTA) was performed in most participants with eGFR ≥60 mL/min/1.73m2 to identify and exclude participants with either significant unprotected left main disease (≥50% stenosis) or those without obstructive CAD (\<50% stenosis in all major coronary arteries). Of 8518 participants enrolled, those that had insufficient ischemia, ineligible anatomy demonstrated on CCTA or another exclusion criterion, did not go on to randomization. Eligible participants were then assigned at random to a routine invasive strategy (INV) with cardiac catheterization followed by revascularization, if feasible, plus optimal medical therapy (OMT) or to a conservative strategy (CON) of OMT, with cardiac catheterization and revascularization reserved for those who fail OMT. SPECIFIC AIMS A. Primary Aim The primary aim of the ISCHEMIA trial is to determine whether an initial invasive strategy of cardiac catheterization followed by optimal revascularization, if feasible, in addition to OMT, will reduce the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure in participants with SIHD and moderate or severe ischemia over an average follow-up of approximately 3.5 years compared with an initial conservative strategy of OMT alone with catheterization reserved for failure of OMT. B. Secondary Aims Secondary aims are to determine whether an initial invasive strategy compared to a conservative strategy will improve: 1) the composite of CV death or MI; 2) angina symptoms and quality of life, as assessed by the Seattle Angina Questionnaire; 3) all-cause mortality

Interventions

  • BEHAVIORAL Lifestyle
  • PROCEDURE cardiac catheterization
  • PROCEDURE coronary artery bypass graft surgery
  • PROCEDURE percutaneous coronary intervention
  • DRUG Medication

Study Locations (20)

California

  • Cedars Sinai Medical Center - Beverly Hills
  • UCSF - Fresno Community Regional Medical Center - Fresno
  • Ronald Reagan UCLA Medical Center - Los Angeles
  • University of California Irvine Medical Center - Orange
  • Palo Alto Medical Foundation Research Institute - Palo Alto
  • VA Palo Alto HealthCare System - Palo Alto
  • Kaiser Permanente San Jose - San Jose
  • Coastal Heart Medical Group - Santa Ana
  • Stanford University School of Medicine - Stanford
  • Torrance Memorial Medical Center - Torrance

Florida

  • Daytona Heart Group - Daytona Beach
  • Malcom Randall VAMC - Gainesville
  • Mayo Clinic Florida - Jacksonville
  • Cardiovascular Center of Sarasota - Sarasota
  • Sarasota Memorial Hospital - Sarasota

Colorado

  • South Denver Cardiology Associates, P.C. - Littleton
  • Medical Center of the Rockies - Loveland

Alabama

  • UAB Vascular Biology and Hypertension Program - Birmingham

Arizona

  • Yuma Regional Medical Center - Yuma

Connecticut

  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 5,179 participants
Start Date 2012-07
Est. Completion 2023-05-30
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT01471522

The ClinicalTrials.gov registry entry for NCT01471522 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5,179 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,957-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (81% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 5 interventions - of which Lifestyle is the first listed.

NCT01471522 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT01471522 about?

NCT01471522 is a clinical study titled "International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)". The purpose of the ISCHEMIA trial is to determine the best management strategy for higher-risk patients with stable ischemic heart disease (SIHD). This is a multicenter randomized controlled trial with 5179 randomized participants with moderate or severe ischemia on stress testing. A blinded coronar...

What is the current status of trial NCT01471522?

This trial is currently completed. It is a NA study. The enrollment target is 5,179 participants. The study started on 2012-07. Estimated completion is 2023-05-30.

What conditions does trial NCT01471522 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Coronary Disease, Myocardial Ischemia.

What interventions are being tested in trial NCT01471522?

The interventions under investigation include: Lifestyle (BEHAVIORAL), cardiac catheterization (PROCEDURE), coronary artery bypass graft surgery (PROCEDURE), percutaneous coronary intervention (PROCEDURE), Medication (DRUG).

Who is sponsoring clinical trial NCT01471522?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01471522 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.